文献速递神经肿瘤

脑膜瘤颅外转移的系统综述:时机、演变与展望

A systematic review of extraneural meningioma metastasis: timing, evolution and outlook.
PubMed 文献 · J Neurooncol · 2024-03-26

本系统综述检索多个数据库至2024年2月23日,纳入288例颅外转移性脑膜瘤患者,分析人口学、临床特征、治疗与结局。多数患者有颅内复发(79%),首次转移平均时间约8年,65%病例原发与转移灶WHO分级无变化。全队列中位生存36个月,WHO 1级与2/3级原发者差异显著(168 vs. 15个月,p<0.005)。

要点

  • 颅外转移性脑膜瘤患者中位生存36个月,WHO 1级原发者生存显著优于2/3级(168 vs. 15个月,p<0.005)。
  • 多数患者(79%)发生颅内复发,首次转移平均时间约8年。
  • 65%病例原发与转移灶之间WHO分级无变化。

核心结论

  • 转移性脑膜瘤的预后似乎优于其他类型脑肿瘤的颅外转移或一般转移,尤其是起源于WHO 1级脑膜瘤的病例。

研究设计与样本

  • 系统综述,检索PubMed、EMBASE、Scopus、Cochrane和Web of Science数据库自建库至2024年2月23日,按PRISMA指南纳入288例转移性脑膜瘤患者,采用描述性统计、Mann-Whitney U检验、Fisher精确检验、Kaplan-Meier曲线和log-rank检验分析。

主要发现

  • 共纳入288例患者(52%为男性),脑膜瘤诊断时平均年龄49岁。
  • 肿瘤WHO分级分布为1级38%、2级36%、3级26%。
  • 大多数患者(79%)经历颅内复发,首次转移的平均时间约为8年。
  • 大多数病例(65%)原发与转移灶之间WHO分级无变化。
  • 初次转移的治疗最常见为手术(43%)、化疗(20%)或无治疗(14%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Extraneural meningioma metastasis is a rare occurrence and may pose a clinical challenge due to its unclear prognosis. In this systematic review, we analyze patient demographics, clinical characteristics, management strategies, and outcomes. METHODS: PubMed, EMBASE, Scopus, Cochrane, and Web of Science databases were searched from inception to February 23, 2024 for cases of metastatic meningioma according to PRISMA guidelines. Descriptive statistics, Mann-Whitney U test, Fisher's exact tests, Kaplan-Meier curves, and log-rank tests were used for selected analyses. RESULTS: A total of 288 patients (52% male) were included with an average age of 49 years at meningioma diagnosis. Tumors were distributed across WHO grade 1 (38%), 2 (36%), and 3 (26%). Most patients experienced intracranial recurrence (79%) and mean time to first metastasis was approximately 8 years. No change in WHO grade between primary and metastasis was observed for most cases (65%). Treatment of the initial metastasis was most often with surgery (43%), chemotherapy (20%), or no treatment (14%). Half of the patients were alive (50%) with an average follow-up of 3 years following metastasis. Overall median survival was 36 months for the entire cohort. This differed significantly between WHO grade 1 versus 2/3 meningioma primaries (168 vs. 15 months, p < 0.005). CONCLUSION: Metastatic meningioma appears to be associated with more positive prognosis than other brain tumor types with extra-neural metastasis or metastasis in general. This is particularly true for cases arising from a WHO grade 1 meningioma.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Watanabe G, Young K, Rauber E, et al. A systematic review of extraneural meningioma metastasis: timing, evolution and outlook. J Neurooncol. 2024. PMID: 38530549. doi:10.1007/s11060-024-04659-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。